Galapagos NV (NASDAQ:GLPG) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, GLPG to report 3Q20 loss of $ 1.23 per share.
For the full year, analysts anticipate top line of $ 644.51 million, while looking forward to loss of $ 5.15 per share bottom line.
Previous Quarter Performance
Galapagos NV recorded loss for the second quarter of $ 1.95 per share, from the revenue of $ 114.09 million. Street analysts expected Galapagos NV to report loss of $ 1.10 per share on revenue of $ 142.77 million for the second quarter. The bottom line results missed street analysts by $ 0.85 or 77.27 percent, at the same time, top line results fell short of analysts by $ 28.68 million or 20.09 percent.
Stock Performance
Shares of Galapagos NV traded up $ 4.97 or 4.12 percent on Wednesday, reaching $ 125.48 with volume of 448.00 thousand shares. Galapagos NV has traded high as $ 127.81 and has cracked $ 124.64 on the downward trend
The closing price of $ 125.48, representing a 7.60 % increase from the 52 week low of $ 112.00 and a 56.02 % decrease over the 52 week high of $ 274.03.
The company has a market capital of $ 8.15 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 159.00 target price.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The companys clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis, Crohns disease, and ulcerative colitis; Phase II trials for small bowel CD, fistulizing CD, Sjögrens syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. Its clinical stage programs also comprise GLPG1690I, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof of concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF.
